InventisBio

InventisBio (益方生物, 688382.SH) is a Shanghai-listed innovative drug developer backed by Qiming Venture Partners and BlueRun Ventures' biotech team, whose early investors' track record included it alongside names like 微芯生物 and 凯赛生物 . Its lead assets are the highly selective oral KRAS G12C inhibitor garsorasib (格索雷塞), which reported progress in KRAS G12C-mutant advanced solid tumors in mid-2025, and the TYK2 inhibitor D-2570 (nomelcitinib), for which it presented oral late-breaking Phase 2 psoriasis data at the 2025 AAD annual meeting and dosed the first patient in a Phase 2 ulcerative colitis trial that May . It was also among the early adopters of DeepWise's physics-modeling-plus-AI computational platform for preclinical drug R&D, per a Source Code Capital piece , and appeared on VBData's 2026 Future Healthcare 100 list as a Qiming portfolio company . Note the corpus holds no founding-date, team, or fundraising-history detail on the company itself — the material here is almost entirely Qiming's portfolio updates.